ARTICLE | Company News

Sepracor, Abbott sales and marketing update

November 22, 1999 8:00 AM UTC

The companies will co-promote SEPR's Xopenex levalbuterol beta agonist to treat reversible bronchospasm. Abbott will promote Xopenex to U.S. pediatricians and SEPR will market the product to U.S. pulmonologists, allergists and primary care physicians. SEPR will be credited with all sales and Abbott will receive a commission on pediatric sales. ...